Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Immuno
Special Issues
Adoptive T-Cell Therapy against Solid Tumors
share announcement

Adoptive T-Cell Therapy against Solid Tumors

A special issue of Immuno (ISSN 2673-5601).

Deadline for manuscript submissions: closed (30 November 2022) | Viewed by 15798

Special Issue Editor

Prof. Dr. Niels Schaft

E-Mail Website
Guest Editor
Department of Dermatology, Universitätsklinikum Erlangen, 91054 Erlangen, Germany
Interests: CAR-T cells; melanoma; adoptive cell therapy; cancer vaccination; cancer immunotherapy; solid tumors
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Tumor-antigen-specific cytotoxic T lymphocytes (CTL) play a key role in tumor immunology. Therefore, the generation of these cells to support the often-crippled immune system of the patient has been the main aim in the cellular adoptive immunotherapy of cancer. The transferred cells range from tumor-infiltrating lymphocytes (TIL) to T cells reprogrammed with a tumor-antigen specificity by transfer of a T-cell receptor (TCR) or chimeric antigen receptor (CAR). The latter strategy in particular has proven to be very efficient in the treatment of hematologic tumors. However, the efficacy against solid tumor lags behind. Therefore, this Special Issue will focus on improvements and new strategies of adoptive T-cell therapy against solid tumors.   

Immuno is a new international, peer-reviewed scientific open-access journal that provides an advanced forum for studies related to basic and clinical immunology research published quarterly online by MDPI.

Authors are cordially invited to contribute original research papers or reviews to this Special Issue of Immuno.

Prof. Dr. Niels Schaft
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Immuno is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Solid tumor
  • TIL
  • TCR transfer
  • CAR-T cells
  • Tumor microenvironment
  • CAR format
  • Targeted antigens

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

20 pages, 1278 KiB  
Review
Combining CAR T Cell Therapy and Oncolytic Virotherapy for Pediatric Solid Tumors: A Promising Option
by Jiasen He, Faryal Munir, Dristhi Ragoonanan, Wafik Zaky, Sajad J Khazal, Priti Tewari, Juan Fueyo, Candelaria Gomez-Manzano and Hong Jiang
Immuno 2023, 3(1), 37-56; https://doi.org/10.3390/immuno3010004 - 20 Jan 2023
Cited by 3 | Viewed by 3593
Abstract
Despite advances in treatment options, the clinical outcomes of pediatric patients with advanced solid tumors have hardly improved in decades, and alternative treatment options are urgently needed. Innovative therapies, such as chimeric antigen receptor (CAR) T cells and oncolytic viruses (OVs), are currently [...] Read more.
Despite advances in treatment options, the clinical outcomes of pediatric patients with advanced solid tumors have hardly improved in decades, and alternative treatment options are urgently needed. Innovative therapies, such as chimeric antigen receptor (CAR) T cells and oncolytic viruses (OVs), are currently being evaluated in both adults and children with refractory solid tumors. Because pediatric solid tumors are remarkably diverse and biologically different from their adult counterparts, more research is required to develop effective treatment regimens for these patients. Here, we first summarize recent efforts and advances in treatments for pediatric solid tumors. Next, we briefly introduce the principles for CAR T cell therapy and oncolytic virotherapy and clinical trials thereof in pediatric patients. Finally, we discuss the basis for the potential benefits of combining the two approaches in pediatric patients with advanced solid tumors. Full article
(This article belongs to the Special Issue Adoptive T-Cell Therapy against Solid Tumors)
►▼ Show Figures

Figure 1

18 pages, 989 KiB  
Review
ACT Up TIL Now: The Evolution of Tumor-Infiltrating Lymphocytes in Adoptive Cell Therapy for the Treatment of Solid Tumors
by Thomas Morgan Hulen, Christopher Aled Chamberlain, Inge Marie Svane and Özcan Met
Immuno 2021, 1(3), 194-211; https://doi.org/10.3390/immuno1030012 - 09 Jul 2021
Cited by 9 | Viewed by 10531
Abstract
The past decades of cancer immunotherapy research have provided profound evidence that the immune system is capable of inducing durable tumor regression. Although many commercialized anti-cancer immunotherapies are available to patients, these treatment options only scrape the surface of the potential immune-related treatment [...] Read more.
The past decades of cancer immunotherapy research have provided profound evidence that the immune system is capable of inducing durable tumor regression. Although many commercialized anti-cancer immunotherapies are available to patients, these treatment options only scrape the surface of the potential immune-related treatment possibilities for cancer. Additionally, many individuals are ineligible for established immunotherapies due to their cancer type. The adoptive cell transfer of autologous tumor-infiltrating lymphocytes has been used in humans for over 30 years to treat metastatic melanoma, and continued modifications are making it increasingly more effective against other types of cancer. This comprehensive review outlines this therapy from its infancy through to the present day, bringing to light modifications and optimizations to the traditional workflow, as well as highlighting the influence of new methods and technologies. Full article
(This article belongs to the Special Issue Adoptive T-Cell Therapy against Solid Tumors)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop